Le Lézard
Classified in: Health

Community Psychiatry Opens Four New TMS Treatment Centers in California

SACRAMENTO, Calif., Aug. 13, 2020 /PRNewswire-PRWeb/ -- Community Psychiatry Management, LLC, the largest outpatient mental health organization in California with more than 40 offices, today announced the availability of Transcranial Magnetic Stimulation (TMS) therapy through its practices in San Jose, Roseville, Davis and Del Mar, California. Community Psychiatry now offers TMS treatments at seven locations statewide, including Sacramento, and two of California's most experienced TMS treatment centers in Calabasas and Simi Valley.

TMS is a safe, non-invasive, non-systemic FDA-cleared treatment for Major Depressive Disorder and Obsessive Compulsive Disorder. The TMS device generates a pulsed magnetic field, similar to that of a magnetic resonance imaging (MRI) machine. TMS works by stimulating underactive nerve cells in brain regions known to regulate mood, helping to reset brain chemistry. The typical treatment course consists of approximately 20-minute sessions, five days a week over a six-week period. There is no sedation involved and there is no downtime. Since its FDA-clearance in 2008, TMS has been well-regarded by the medical community as a safe and effective alternative treatment for depression and does not have any of the side effects commonly seen with medication.

According to the National Institute of Mental Health, 17.3 million Americans are diagnosed with Major Depressive Disorder annually. "While therapy and medications can be very effective in helping those with depression, up to 40% of patients do not receive adequate relief from these treatments," said psychiatrist Dr. Robert Trimmer, M.D. "TMS is an incredibly safe and effective treatment option for patients with treatment-resistant depression, does not carry many of the side effects potentially caused by antidepressants, and can give many of these patients a new lease on life. We are very pleased to make TMS treatment available to our patients in even more locations throughout California."

"The opening of our new TMS centers brings Community Psychiatry to the forefront of exceptional mental health care in California and highlights what we value above all: compassion, trustworthiness and providing excellent patient care," said Dr. Priyanka, M.D., Medical Director for Community Psychiatry. "We are committed to expanding access to TMS treatment and proud to offer this groundbreaking technology and safe treatment to our patients who need it most."

TMS is changing the future of psychiatry through advanced technology that gives patients relief from major depression. TMS is covered by most insurance companies for major depression. For more information about TMS at Community Psychiatry, call 866-317-7282 or visit https://www.communitypsychiatry.com.

About Community Psychiatry
For more than a decade, Community Psychiatry has been increasing access to mental health care for Californians by creating cooperative relationships with patients, physicians, psychotherapists, hospitals and insurers. The company currently employs over 120 psychiatrists, psychiatric nurse practitioners, psychologists and licensed therapists who provide connected care through telemedicine and in-person visits at more than 40 locations across California. Community Psychiatry is dedicated to providing high-quality, in-network mental health services through its partnerships with the majority of commercial health insurance providers (20+) in California.

Follow us on Twitter, Facebook, Instagram and LinkedIn, or learn more at communitypsychiatry.com.


SOURCE Community Psychiatry

These press releases may also interest you

at 13:41
The U.S. Conference of Mayors (USCM) is again urging congressional and administration leaders to return to the negotiating table and pass a bipartisan COVID-19 relief package that includes emergency fiscal assistance to cities of all sizes.  American...

at 13:35
Medtronic  has won an important victory in a patent dispute over intellectual property for its sacral neuromodulation device family, the InterStimtm systems. The Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office rejected in...

at 13:30
RemeGen Co., Ltd. ("RemeGen") today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for disitamab vedotin (RC48), a novel humanized anti-HER2 antibody drug conjugate (ADC), for the second-line...

at 13:30
Novo Seeds, the early stage investment and company creation team of Novo Holdings, today announced that its portfolio company Galecto Inc. (Galecto), a privately-held biotechnology company focused on the development of novel treatments for fibrosis...

at 13:09
AMDT Holdings, Inc. develops disruptive products to address existing and emerging needs in the extremity market. The flagship products for AMDT Holdings are the patented SixFix® Circular Fixation System, the patented SixFix Deformity Analysis and...

at 13:05
Gilead Sciences, Inc. and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the European Commission (EC) has granted marketing authorization for Jyseleca® (filgotinib 200 mg and 100 mg tablets), a once-daily, oral, JAK1 inhibitor for the...

News published on 13 august 2020 at 12:10 and distributed by: